CardioComm Solutions' HeartCheck (tm) Technologies to be Used in Canadian Parkinson's Research Study. Second CIHR and Indust...
05 Dezembro 2013 - 7:21PM
Access Wire
Toronto, Canada -
CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or
the "Company"), a global medical provider of electrocardiogram
("ECG") acquisition and management software solutions, announced it
shall be providing HeartCheckTM
based ECG screening technologies to researchers from
the Research Institute of the McGill University Health Centre (RI
MUHC) and the Montreal General Hospital (Quebec, Canada). This
research study, which will be funded by the Canadian Institutes of
Health Research (CIHR) and the Webster Foundation, will evaluate
the potential relationship between caffeine intake and improvements
in motor symptoms of persons with Parkinson's disease
("PD").
The study, entitled "Caffeine for
Motor Manifestations of Parkinson's Disease: An Open-Label
Dose-Response Study," builds on prior research that examined the
benefits of caffeine on motor impairment in people who have PD. A
total of 250 PD patients with a disease duration of one (1) to six
(6) years who have been on stable symptomatic therapy for six (6)
months, have been free of dementia or severe depression and who
have a baseline caffeine intake of 150mg per day will be screened
for ECG abnormalities, and specifically supraventricular
tachycardia, prior to entry into the study. "In this current
research study, all patients will be screened by performing an
electrocardiogram ("ECG") in our neurology clinic to ensure against
the presence of supraventricular arrhythmias," stated Dr. Ronald
Postuma, lead author of the study, a researcher in neurosciences at
the RI MUHC, and Professor of Medicine in the Department of
Neurology and Neurosurgery at McGill University.
"We are pleased to
have been selected to participate in this research project, which
is our second opportunity to work with researchers supported by
CIHR funding. The opportunity to expand the use of our technologies
beyond cardiology centred projects provides independent scientific
validation of the utility of our technologies and software as ECG
screening and monitoring solutions. Dr. Postuma and his team will
be using our HeartCheckTM ECG monitors to collect 30 second ECG recordings which will then
be transferred to our patent pending SMART Monitoring ECG service
via GEMS Home 1.2. Last month we extended the capacity of GEMS Home
1.2 to support the prescription version of our
HeartCheckTM devices.
Once transferred to GEMS Home, ECG records will be coded using
study subject IDs and then uploaded to our SMART Monitoring servers
where the researchers will log in to review and interpret their
patient's ECGs themselves. This ability to determine how the SMART
Monitoring ECG service is configured, based on required work flow,
speaks to the power and stability of our services," said Etienne
Grima, Chief Executive Officer for CardioComm Solutions.
"CardioComm Solutions will continue in its efforts to expand use
of its HeartCheckTM and
SMART Monitoring technologies through research, pharmacy and
consumer-based HeartCheckTM
Partner Program distribution efforts in Canada and
the USA. Recent interest has included monitoring of post cardiac
ablation patients for recurrent atrial fibrillation, monitoring of
arrhythmias in heart failure patients in long-term care facilities
and continued public screening programs," said Mr. Simi Grosman,
member of the Board of Directors of the Company.
About CardioComm Solutions
CardioComm Solutions' patented and
proprietary technology is used in products for recording, viewing,
analyzing and storing electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products are sold worldwide through
a combination of an external distribution network and a North
American-based sales team. The Company has earned the ISO 13485
certification, is HPB approved, HIPAA compliant, and has received
FDA market clearance for its software devices. CardioComm
Solutions, Inc. is headquartered in Toronto, Canada, with offices
in Victoria, B.C.
For Further Information On
Cardiocomm Solutions Please Contact:
Etienne Grima, Chief Executive
Officer
1-877-977-9425
egrima@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain
forward-looking statements with respect to the financial condition,
results of operations and business of CardioComm Solutions and
certain of the plans and objectives of CardioComm Solutions with
respect to these items. By their nature, forward-looking statements
involve risk and uncertainty because they relate to events and
depend on circumstances that will occur in the future and there are
many factors that could cause actual results and developments to
differ materially from those expressed or implied by these
forward-looking statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
CardioComm Solutions (TSXV:EKG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
CardioComm Solutions (TSXV:EKG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024